GNPX

Genprex Inc

GNPX, USA

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is based in Austin, Texas.

https://www.genprex.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GNPX
stock
GNPX

Congressman Buys Shares Of Small Cap Lift Truck Company You've Probably Never Heard Of Benzinga

Read more →
GNPX
stock
GNPX

Genprex, Inc. Stock (GNPX) Opinions on Recent Preclinical Data Release Quiver Quantitative

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$7.5

Analyst Picks

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

0.10

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

High

2.37

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-494.82 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-106.64 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very Low

3.64

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 3.40% of the total shares of Genprex Inc

1.

Susquehanna International Group, LLP

(0.9095%)

since

2025/06/30

2.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8889%)

since

2025/07/31

3.

UBS Group AG

(0.3921%)

since

2025/06/30

4.

Fidelity Extended Market Index

(0.387%)

since

2025/07/31

5.

Geode Capital Management, LLC

(0.2247%)

since

2025/06/30

6.

Virtu Financial LLC

(0.1288%)

since

2025/06/30

7.

TWO SIGMA SECURITIES, LLC

(0.0644%)

since

2025/06/30

8.

Fidelity Series Total Market Index

(0.0502%)

since

2025/07/31

9.

Eqis Capital Management Inc

(0.0495%)

since

2025/06/30

10.

TCG Advisory Services, LLC

(0.0463%)

since

2025/06/30

11.

Vanguard Group Inc

(0.0458%)

since

2025/06/30

12.

Spartan Total Market Index Pool G

(0.045%)

since

2025/07/31

13.

HighTower Advisors, LLC

(0.0418%)

since

2025/06/30

14.

Citigroup Inc

(0.0377%)

since

2025/06/30

15.

BlackRock Inc

(0.0283%)

since

2025/06/30

16.

Tower Research Capital LLC

(0.0179%)

since

2025/06/30

17.

SBI Securities Co Ltd

(0.0072%)

since

2025/06/30

18.

Fidelity Total Market Index

(0.0051%)

since

2025/07/31

19.

EC SICAV EverCapital Invms UCITS I Ins I

(0.0045%)

since

2025/07/31

20.

NT Ext Equity Mkt Idx Fd - NL

(0.003%)

since

2025/06/30

21.

Morgan Stanley - Brokerage Accounts

(0.0029%)

since

2025/06/30

22.

NT Ext Equity Mkt Idx Fd - L

(0.0027%)

since

2025/06/30

23.

Northern Trust Extended Eq Market Idx

(0.0027%)

since

2025/06/30

24.

Spartan Extended Market Index Pool F

(0.0027%)

since

2025/07/31

25.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0023%)

since

2025/06/30

26.

Bank of America Corp

(0.002%)

since

2025/06/30

27.

State St US Extended Mkt Indx NL Cl C

(0.0012%)

since

2025/08/31

28.

Vanguard U.S. Eq Idx £ Acc

(0.001%)

since

2025/07/31

29.

BNYM Mellon SL Market Completion UC1

(0.001%)

since

2025/06/30

30.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0008%)

since

2025/06/30

31.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0007%)

since

2024/12/31

32.

SSgA U.S. Total Market Index Strategy

(0.0005%)

since

2025/03/31

33.

Hanson Mcclain Inc

(0.0004%)

since

2025/06/30

34.

State St US Ttl Mkt Indx NL Cl A

(0.0004%)

since

2025/08/31

35.

Northern Trust Wilshire 5000

(0.0004%)

since

2025/06/30

36.

Advisor Group Holdings, Inc.

(0.0003%)

since

2025/06/30

37.

Royal Bank of Canada

(0.0002%)

since

2025/06/30

38.

Mount Yale Investment Advisors, LLC

(0.0001%)

since

2025/06/30

39.

FMR Inc

(0.0001%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-5

EPS Estimate

-0.65

EPS Difference

-4.35

Surprise Percent

-669.2308%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Moderately Defensive(4)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(2.8)
GARP
Not Attractive for GARP(0.5)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(1)
Value
Fair Value(5.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.